FindMyKOL

Daniel Salerno, MD

Basic profile

Temple University Hospital

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPhiladelphia, PA · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Last active 2021FindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Daniel Salerno is a Respiratory physician affiliated with Temple University Hospital. OpenAlex indexes 29 publications with 326 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
29publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

326citations

Citations across these publications.

8h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Verona Pharma
    Program year202518 paymentsResearch
    $54,991
  • MannKind
    Program year20254 paymentsResearch
    $39,551
  • Regeneron
    Program year20248 paymentsResearch
    $12,395
All 7 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    65.9%
    Corticosteroid34.5%
    Trelegy Ellipta43%Symbicort19%Breztri Aerosphere19%Breo Ellipta12%Fluticasone Propionate7%
    Part D<11 patients
    beta2-Adrenergic Agonist20.6%
    Albuterol Sulfate Hfa91%Ventolin Hfa9%
    Part D<11 patients

    + 2 more classes in this area

  • Anti-infectives

    17.4%
    Macrolide Antimicrobial9.9%
    Azithromycin100%
    Part D≥29 patients
    Antimycobacterial4.2%
    Ethambutol Hcl100%
    Part D<11 patients

    + 1 more class in this area

  • Metabolism & gastrointestinal

    9.5%
    Corticosteroid9.5%
    Prednisone100%
    Part D≥27 patients
Where care is delivered (Part B)66.6% facility · 33.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”